Fig. 6: BKM120/rucaparib combination treatment inhibits tumor growth in U87MG nude mouse orthotopic xenograft models.

A–F Mice were inoculated with U87MG-Luc cells. The localization and intensity of luciferase expression were monitored by in vivo bioluminescence imaging (dpi, days post cell injection). Following a single dose of BKM120 (30 mg/kg) or rucaparib (10 mg/kg) or combination treatment of BKM120 and rucaparib for 14 days (n = 5), animals were measured by a bioluminescence imaging system. A Representative images of mice taken by the bioluminescence imaging system. B The relative radiance, which represents tumor size, was determined by the imaging system. C Body weights were monitored during the 14 days of treatment. D Hematoxylin and eosin-stained section (original magnification ×20) of intracranial U87MG mouse xenografts following BKM120 and/or rucaparib treatments. Scale bar: 1 mm. E Representative immunohistochemistry staining for BRCA1/2, γ-H2AX, and RAD51 in tumor tissues of U87MG xenografts. Scale bar: 50 μm. F Statistical quantification of (E) shows HR repair efficiency and DNA DSB levels in U87MG xenografts with the indicated treatments. Data are presented as the mean ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001.